Resistin predicts ischemia in myocardial perfusion scintigraphy.

Aim: Resistin plays a role in the pathogenesis of coronary artery disease and is related to mortality and morbidity through a number of mechanisms. We hypothesize that plasma resistin levels are increased in the presence of ischemia, as measured by GATED single-photon emission computed tomography myocardial perfusion scintigraphy (SPECT MPS), in comparison with nonischemic subjects. Materials and methods: Fasting intravenous blood samples of patients were drawn before a stress test. An ELISA kit was used for the assays. All patients underwent a technetium 99m-sestamibi GATED SPECT MPS study with a 1-day stress-rest protocol. Images were analyzed visually and patients were assessed as ischemic or nonischemic. Resistin levels were presented as medians (25th-75th percentiles) and were compared using the Mann-Whitney U test. Results: Plasma resistin levels were higher in the ischemic group (n = 47) than in the nonischemic group (n = 67) [9.04 mu mol/L (6.27-11.8 mu mol/L) vs. 3.56 mu mol/L (0.39-7.93 mu mol/L), respectively; P < 0.001). We showed that plasma resistin levels (OR = 1.26, 95% CI: 1.13-1.41; P < 0.001) and METs (OR = 0.82, 95% CI: 0.70-0.92; P = 0.021) were independent predictors of ischemia. No linear correlation was found between plasma resistin levels and GATED SPECT or stress test parameters. Conclusion: Increased baseline resistin levels are independently related to presence of ischemia but are not related to the extent or severity of ischemia, or other functional parameters such as poststress ejection fraction, end systolic, and end diastolic volumes.